Pharma Focus Europe

The world's first such vaccine: The multivalent recombinant protein vaccine against XBB variant of COVID-19 from WestVac Biopharma

Saturday, May 20, 2023

Bivalent Recombinant COVID-19 Protein Vaccine (Sf9 Cells) and Trivalent Recombinant COVID-19 Trimeric Protein Vaccine (Sf9 Cells) developed by WestVac Biopharma/West China Medical Center, Sichuan University, against the most recent circulating XBB variants, have received "Clinical Drug Trial Approval" from the National Medical Products Administration of China. These two new vaccines will be rapidly commercialized to protect against the XBB variant currently in circulation once the necessary clinical trials have been completed. These two vaccines are also the first COVID-19 vaccines in the world to enter specific clinical trials for variants like XBB.

The Joint Prevention and Control Mechanism of the State Council held a press conference in early May 2023. The assembly noted that with the increasing interaction between China and other countries , the global impact on the composition of the main pandemic variants of the new coronavirus in my country has increased significantly. According to monitoring data [1], the main pandemic variants of the COVID-19 virus in China have evolved into the XBB series. In this context, WestVac Biopharma uses the international advanced recombinant protein vaccine platform on insect cells to develop the bivalent (XBB + prototype strain) recombinant (Sf9 cells) COVID-19 protein vaccine (Sf9 cells) Coviccine ® and the trivalent COVID-19 protein vaccine. (XBB + BA.5 + Delta variant) recombinant (Sf9 cells). Both of WestVac's vaccines are essential for the prevention of current XBB variants and contribute significantly to the current management of the COVID-19 outbreak.

Bivalent recombinant COVID-19 protein vaccine (XBB+Prototype) Coviccine® (Sf9 cells)

The bivalent (XBB+ prototype) COVID-19 recombinant protein vaccine (Sf9 cells) is an improved version of the Coviccine® recombinant COVID-19 vaccine (Sf9 cells) developed by WestVac Biopharma. Studies have shown that the vaccine induces high titers of neutralizing antibodies against multiple subvariants, including XBB.1.5, XBB1.16, XBB1.9.1, XBB.2.3, BA.5, BF.7, BQ.1 [1] , indicating that the vaccine is an effective universal COVID-19 vaccine against multiple strains, notably with a particularly significant increase in neutralizing antibodies against XBB-series variants.

Recombinant trivalent (XBB+BA.5+Delta) COVID-19 trimeric protein vaccine (Sf9 cells)

Leveraging the responsiveness of the world's leading insect cell expression platform in the field of recombinant protein vaccine production, WestVac Biopharma and its subsidiary WestVac Biopharma ( Guangzhou) constructed the trivalent (XBB+BA.5+Delta) recombinant COVID-19 protein vaccine vector (Sf9 cells) and produced high purity and high quality trivalent recombinant protein vaccines for use in 'male. The subunit vaccine antigen is precisely designed based on the structure of the target S-RBD and HR proteins of COVID-19 subvariants XBB and BA.5, and can self-assemble into trimeric protein particles stable. Studies have shown that the vaccine increases titers of neutralizing antibodies targeting subvariants including Omicron XBB.1.5, XBB1.16, XBB1.9.1, XBB.2.3, BA.5, BF.7, BQ.1, BA.2.75, indicating that it is a broad-spectrum COVID-19 vaccine against several subvariants prevalent in the country and in the

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva